Trial Profile
An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 26 Feb 2013 New trial record